The Bcl-2/Bax and Ras/Raf/MEK/ERK signaling pathways: implications in pediatric leukemia pathogenesis and new prospects for therapeutic approaches

References

• Legler JM, Ries LA, Smith MA et al. Cancer surveillance series (corrected): brain and other central nervous system cancers: recent trends in incidence and mortality. J. Natl Cancer Inst. 91(16), 1328–1390 (1991).
   Google Scholar
• Kerr JFR, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and chemotherapy. Cancer 73(8), 2013–2026 (1994).
   PubMed Web of Science ®Google Scholar
• Kelly PN, Strasser A. The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ. 18(9), 1414–1424 (2011).
   PubMed Web of Science ®Google Scholar
• D'Angelo V, Crisci S, Casale F et al. High Erk-1 activation and Gadd45a expression as prognostic markers in high risk pediatric haemolymphoproliferative diseases. J. Exp. Clin. Cancer Res. 19, 28–39 (2009).
   Google Scholar
• Kirkin V, Joos S, Zörnig M. The role of Bcl-2 family members in tumor genesis Biochim. Biophys. Acta 1644(2–3), 229–249 (2004).
   PubMedGoogle Scholar
• Borner C. The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol. Immunol. 39, 615–647 (2003).
   PubMed Web of Science ®Google Scholar
• Métais JY, Winkler T, Geyer JT et al. BCL2A1a over-expression in murine hematopoietic stem and progenitor cells decreases apoptosis and results in hematopoietic transformation. PLoS ONE 7(10), e48267 (2012).
   Web of Science ®Google Scholar
• Krajewski S, Krajewska M, Shabaik A, Miyashita T, Wang HG, Reed JC. Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2, Am. J. Pathol. 145, 1323–1336 (1994).
   PubMed Web of Science ®Google Scholar
• Krajewski S, Krajewska M, Reed JC. Immunoistochemical analysis of in vivo patterns of Bax expression, a proapoptotic member of Bcl-2 protein family. Cancer Res. 56, 2849–2855 (1996).
   PubMed Web of Science ®Google Scholar
• Griffiths GJ, Dubrez L, Morgan CP et al. Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis. J. Cell Biol. 144(5), 903–914 (1999).
   PubMed Web of Science ®Google Scholar
• Grinberg M, Sarig R, Zaltsman Y et al. tBID Homooligomerizes in the mitochondrial membrane to induce apoptosis. J. Biol. Chem. 277(14), 12237–12245 (2002).
   PubMed Web of Science ®Google Scholar
• Wei CM, Lindsten T, Mootha VK et al. tBID, a membrane-targeted death ligand, ligomerizes BAK to release cytochrome c. Genes Dev. 14(16), 2060–2071 (2000).
   PubMed Web of Science ®Google Scholar
• Yamaguchi H, Wang HG. Bcl-XL protects BimEL-induced Bax conformational change and cytochrome c Release Independent of Interacting with Bax or BimEL. J. Biol. Chem. 277(44), 41604–41612 (2002).
   PubMed Web of Science ®Google Scholar
• Del Gaizo Moore V, Letai A. BH3 profiling--measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett. 332(2), 202–205 (2013).
   PubMed Web of Science ®Google Scholar
• Case M, Matheson E, Minto L et al. Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia. Cancer Res. 68, 6803–6809 (2008).
   PubMed Web of Science ®Google Scholar
• Sebolt-Leopold JS, Pfizer Global Research and Development Ann Arbor Laboratories, Ann Arbor, Michigan, MI, USA. Development of anticancer drugs targeting the MAP kinase pathway, 48105, Oncogene 19, 6594–6599 (2000).
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Steelman LS, Chappell WH et al. Roles of the RAF/MEK/ERK Pathway in cell growth, Malignant transformation and drug resistance. Biochim. Biophys. Acta 1773(8), 1263–1284 (2007).
   PubMed Web of Science ®Google Scholar
• Addeo R, Caraglia M, Baldi A et al. Prognostic role of bcl-xL and p53 in childhood acute lymphoblastic leukemia (ALL). Cancer Biol. Ther. 4(1),32–38 (2005).
   PubMed Web of Science ®Google Scholar
• Casale F, Addeo R, D'Angelo V et al. Determination of the in vivo effects of prednisone on Bcl-2 family protein expression in childhood acute lymphoblastic leukemia. Int. J. Oncol. 22(1), 123–128 (2003).
   PubMed Web of Science ®Google Scholar
• Addeo R, Crisci S, D'Angelo V et al. Bax mutation and overexpression inversely correlate with immature phenotype and prognosis of childhood germ cell tumors. Oncol. Rep. 17(5), 1155–1161 (2007).
   PubMed Web of Science ®Google Scholar
• Tolcher AW. Targeting Bcl-2 protein expression in solid tumors and hematologic malignancies with antisense oligonucleotides. Clin. Adv. Hematol.Oncol. 3(8), 635–642 (2005).
   PubMedGoogle Scholar
• Rahmani M, Aust MM, Attkisson E, Williams DCJr, Ferreira-Gonzalez A, Grant S. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. Cancer Res. 73(4), 1340–1345 (2013).
   PubMed Web of Science ®Google Scholar
• Chang F, Steelman LS, Lee JT et al. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 17(7), 1263–1293 (2003).
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Steelman RA, Franklin ASL et al. Targeting the RAF/MEK/ERK, PI3K/AKT and P53 pathways in hematopoietic drug resistance Adv. Enzyme Regul. 47, 64–103 (2007).
   PubMedGoogle Scholar
• De Luca A, Maiello M, D’Alessio A, Pergameno M, Normanno N. The RAS/RAF/MEK/ERK and PI3K/akt signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin. Ther. Targets 16(Suppl. 2), S17–S27 (2012).
   PubMed Web of Science ®Google Scholar
• Oltersdorf T, Elmore SW, Shoemaker AR et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435(7042), 677–681 (2007).
   Web of Science ®Google Scholar
• Lock R, Carol H, Houghton PJ et al. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr. Blood Cancer 50(6), 1181–1189 (2008).
   PubMed Web of Science ®Google Scholar
• Klasa RJ, Gillum AM, Klem RE, Frankel SR. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev. 12(3), 193–213 (2002).
   PubMedGoogle Scholar
• Vandenberg CJ, Cory S. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood 121(12), 2285–2288 (2013).
   PubMed Web of Science ®Google Scholar
• Jansen B, Wacheck V, Heere-Ress E et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 356, 1728–1733 (2000).
   PubMed Web of Science ®Google Scholar
• Badros A, Ratterree B, Natt S et al. Phase I/II trial of Oblimersen sodium (G3139), dexamethasone (Dex) and thalidomide (Thal) in patients with relapsed multiple myeloma. Blood 102, 684a (2003).
   Web of Science ®Google Scholar
• Szegedi I, Katona K, Horváth A, Molnár A, Aradi J, Csongor K. Bcl-2 Antisense Oligonucleotide Inhibits the Proliferation of Childhood Leukemia/lymphoma Cells of the B-cell Lineage Pathol. Oncol. Res. 14(3), 275–279 (2008).
   Web of Science ®Google Scholar
• Bourguin JP. Have chemosensitizing strategies for multidrug-resistant childhood acute lymphoblastic leukemia come of age? Expert Rev. Hematol. 3(4), 369–372 (2010).
   PubMed Web of Science ®Google Scholar
• Kelly PN, Strasser A. The role of Bcl-2 and its pro-survival relatives in tumorigenesis and cancer therapy. Cell Death Differ. 18(9), 1414–1424 (2011).
   PubMed Web of Science ®Google Scholar
• Rahmani M, Aust MM, Attkisson E, Williams DCJr, Ferreira-Gonzalez A, Grant S. Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process. Blood 119(25), 6089–6098 (2012).
   PubMed Web of Science ®Google Scholar
• Patty Feist, MS Biochemistry ALL-kids Targeted Therapies for Childhood ALL December 2010-January 2011.
   Google Scholar
• Clarke MF, Apel IJ, Benedict MA et al. A recombinant bcl-x s adenovirus selectively induces apoptosis in cancer cells but not in normal bone marrow cells. Proc. Natl Acad. Sci. USA 92(24), 11024–11028 (1995).
   PubMed Web of Science ®Google Scholar
• Case M, Matheson E, Minto L et al. Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia. Cancer Res. 68, 6803–6809 (2008).
   PubMed Web of Science ®Google Scholar
• Baum K, Ren R. Effect of Ras inhibition in hematopoiesis and BCR/ABL leukemogenesis. J. Hematol. Oncol. 1,5 (2008).
   PubMed Web of Science ®Google Scholar
• Fenaux P, Raza A, Mufti GJ et al. A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. Blood 109, 4158–4163 (2007).
   PubMed Web of Science ®Google Scholar
• Lancet JE, Gojo I, Gotlib J et al. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood 109, 1387–1394 (2007).
   PubMed Web of Science ®Google Scholar
• Bosco R, Rabusin M, Voltan R et al. Anti-leukemic activity of dasatinib in both p53(wild-type) and p53(mutated) B malignant cells. Invest. New Drugs 30(1), 417–422 (2012).
   PubMed Web of Science ®Google Scholar
• Akinleye A, Furqan M, Mukhi N, Ravella P, Liu D. MEK and the inhibitors: from bench to bedside. J. Hematol. Oncol. 6, 27 (2013).
   PubMed Web of Science ®Google Scholar
• Ricciardi M.R, Scerpa MC, Bergamo P et al. Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for “vertical” and “lateral” combination strategies. J. Mol. Med. 90(10), 1133–1144 (2012).
   PubMed Web of Science ®Google Scholar
• Jing J, Greshock J, Holbrook JD et al. Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212. Mol. Cancer Ther. 11(3), 720–729 (2012).
   PubMed Web of Science ®Google Scholar
• Yeh TC, Marsh V, Bernat BA et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinasekinase 1/2 inhibitor. Clin. Cancer Res. 13(5), 1576–1583 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang W, Konopleva M, Burks JK et al. Blockade of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase and murine double minute synergistically induces Apoptosis in acute myeloid leukemia via BH3-only proteins Puma and Bim. Cancer Res. 70(6), 2424–2434 (2010).
   PubMed Web of Science ®Google Scholar
• Hatzivassiliou G, Spoerke JM, Hoeflich KP et al. ERK inhibition overcomes acquired resistance to MEK inhibitors. Mol. Cancer Ther. 11(5), 1143–1154 (2012).
   PubMed Web of Science ®Google Scholar
• Wei J, Stebbins JL, Kitada S et al. BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J. Med. Chem. 53(10), 4166–4176 (2010).
   PubMed Web of Science ®Google Scholar
• Laquerre S, Arnone M, Moss K et al. A selective Raf kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding B-RafV600E mutation. Mol. Cancer Ther. 8, Abstract B88 (2009).
   Web of Science ®Google Scholar
• Greger JG, Eastman SD, Zhang V et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol. Cancer Ther. 11(4), 909–920 (2012).
   PubMed Web of Science ®Google Scholar